BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32905297)

  • 1. Prevalence of
    Ataseven B; Tripon D; Rhiem K; Harter P; Schneider S; Heitz F; Baert T; Traut A; Pauly N; Ehmann S; Plett H; Schmutzler RK; du Bois A
    Geburtshilfe Frauenheilkd; 2020 Sep; 80(9):932-940. PubMed ID: 32905297
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
    Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
    Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline and Somatic
    You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
    Front Oncol; 2020; 10():295. PubMed ID: 32211327
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    Sung PL; Wen KC; Chen YJ; Chao TC; Tsai YF; Tseng LM; Qiu JT; Chao KC; Wu HH; Chuang CM; Wang PH; Huang CF
    PLoS One; 2017; 12(9):e0185615. PubMed ID: 28961279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).
    Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA
    BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.